Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
McKinsey
Accenture
Medtronic
Colorcon
Queensland Health
Dow
UBS

Generated: May 22, 2018

DrugPatentWatch Database Preview

Horizon Pharma Company Profile

« Back to Dashboard

Summary for Horizon Pharma
International Patents:252
US Patents:55
Tradenames:7
Ingredients:7
NDAs:8
Patent Litigation for Horizon Pharma: See patent lawsuits for Horizon Pharma

Drugs and US Patents for Horizon Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 9,198,888 ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No 8,557,285 ➤ Sign Up Y ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 9,220,698 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Horizon Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 5,900,424*PED ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 5,714,504*PED ➤ Sign Up
Horizon Pharma Inc BUPHENYL sodium phenylbutyrate POWDER;ORAL 020573-001 Apr 30, 1996 4,457,942 ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 6,875,872*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HORIZON PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablet 375 mg/20 mg and 500 mg/20 mg ➤ Subscribe 2010-11-05
➤ Subscribe Topical Solution 1.5% ➤ Subscribe 2012-07-11
➤ Subscribe Topical Solution 2.0% ➤ Subscribe 2014-06-03
➤ Subscribe Tablets 800 mg/26.6 mg ➤ Subscribe 2011-12-06
➤ Subscribe Delayed-release Tablets 1 mg, 2 mg, and 5 mg ➤ Subscribe 2012-11-26

Non-Orange Book US Patents for Horizon Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,364,439 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
8,076,361 Form of S-omeprazole ➤ Sign Up
6,677,455 Potassium salt of S-omeprazole ➤ Sign Up
8,129,433 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Horizon Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/009 Ireland ➤ Sign Up PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
99C0030 Belgium ➤ Sign Up PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C/GB97/078 United Kingdom ➤ Sign Up PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
2014 00013 Denmark ➤ Sign Up PRODUCT NAME: CYSTEAMIN, HERUNDER MERCAPTAMINBITARTRAT; REG. NO/DATE: EU/1/13/861 20130906
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKinsey
US Army
Federal Trade Commission
Merck
Cantor Fitzgerald
Johnson and Johnson
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.